All In Biotech

Drug Trial Radar · NCT07448116

Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.

A Multi-cohort, Open-label Phase I/II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of the Anti-EGFR/c-Met Bispecific Antibody MCLA-129 in Combination With Ensartinib Hydrochloride in Patients With Advanced Solid Tumors.

Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

164

Planned (sponsor's estimate)

Start

Jan 31, 2026

Primary completion

Feb 1, 2029

Study completion Aug 1, 2029

Sponsor

Sponsor type
Industry
First posted
Mar 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of the anti-EGFR/c-Met bispecific antibody MCLA-129 in combination with Ensartinib hydrochloride in patients with advanced solid tumors.

Conditions

  • Solid Advanced Tumor

Interventions

  • MCLA-129Drug

    MCLA-129 is a bispecific antibody that targets both EGFR and c-Met, simultaneously blocking the signaling pathways of both EGFR and c-Met, thereby inhibiting tumor growth and survival.

  • EnsartinibDrug

    Ensartinib acted as a c-MET inhibitor in this study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicity (DLT) in Phase ITime frame: Until 28 days after the first dosing in MCLA-129 1500mg Q2W group or 21 days after the first dosing in MCLA-129 2000mg Q3W group
  2. Maximum Tolerated Dose (MTD) in Phase ITime frame: From date of first treatment until the end of Phase I, approximately 6 months
  3. Treatment-Emergent Adverse Events (TEAE) in Phase ITime frame: From date of first treatment until 30 days after the last dose or the start of other anti-tumor treatment (whichever occurs first)
  4. Overall Response Rate (ORR) in Phase IITime frame: From date of first treatment every 6 weeks until disease progression, death or withdrawal, whichever came first, approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.